Welcome toBrown Retina Institute

Dr. Brown participates in the National Quality of Care Initiative for the Medicare PQRS program.
Click here for more information.

We are committed to providing the best retina care . We do this by providing state-of-the-art retina diagnosis and treatment in a compassionate, caring environment. Our patient centered approach is practiced by everyone in the office. We will always strive to treat you with highest respect and fairness. In addition to treating your condition, we will take the time to explain your diagnosis, treatment plan and future course.

Located in San Antonio, Texas, Dr. Jeremiah Brown is a nationally recognized retina specialist, graduate of Harvard University, author, researcher and father. He is a bilingual, board certified ophthalmologist who has been awarded the American Academy of Ophthalmology Achievement Award. Dr. Brown served with distinction as a vitreoretinal surgeon in the US Army and was awarded the Army Meritorious Service Award. Dr. Brown specializes in many areas, including:

Macular Degeneration
Diabetic Eye Diseases
Eye Procedures
Retinal Diseases

We look forward to having the opportunity to meet with you, discuss your condition and work with you in planning your care.

Call to schedule an appointment today.

Dr. Brown Speaks Spanish


On September 23, 2017, Dr. Brown will lecture to the Macular Degeneration Association in Phoenix, Arizona. The lecture will discuss Diabetes and its effects on the eyes, as well as Latest News in Macular Degeneration. The lecture will be held at 8:30 a.m. at the DoubleTree, 320 N 44th St., Phoenix, AZ 85008.

In TheNews

In April 2017, Lucentis received FDA approval for use in all patients with diabetic retinopathy. Previously, Lucentis could be used in patients with diabetic retinopathy, only they also had diabetic macular edema. The Rise and Ride Clinical Trials demonstrated that not only does Lucentis help to improve macular edema, it also can reverse the progression of retinopathy in up to 38% of patients. Now all patients with diabetic retinopathy can receive this beneficial treatment when appropriate. Brown DM, et al; RISE and RIDE Research Group. Ophthalmology. 2013;120:2013-2022.

View All »

ContactOur Office

  • This field is for validation purposes and should be left unchanged.

Read & SubmitA Review

powered by BirdEye